Pfizer to move into Sydney CBD

Pfizer Australia is to set up in a new, state-of-the-art building in the heart of Sydney.

The company is relocating its Australian office from suburban West Ryde into Barrack Place at 151 Clarence Street in the CBD, a building it says will be one of the most advanced in its class in Sydney when it is completed in 2018.

Pfizer says the building will provide an unprecedented opportunity to change its ways of working and plan for the next generation of its contribution to the health of Australians.

Pfizer will occupy the top four floors of the building. The immediate business precinct is described as a location where many innovative businesses have set up, such as Atlassian and Apple.

“We are proud of our manufacturing legacy at our West Ryde site over the past 60 years,” Pfizer Australia Managing Director Melissa McGregor said.

“Locating Pfizer Australia in this burgeoning business precinct positions us strongly for the next 60 years. We are making a deliberate move to be at the cross-section of society – businesses, government, customers and the general community all intersect in the Sydney CBD.

“We will be part of the innovation and creativity that surrounds the area. In part, because of the location, we will continue to attract vibrant and talented people to work at Pfizer Australia, as we have done for many years.”

Pfizer says the building is being built to first-rate standards in terms of amenities, energy rating and environmental sustainability.

“As it’s a new building, we have the opportunity to design, shape and construct our internal work space to our exacting and unique specifications,” Ms McGregor said. “As you can appreciate, such opportunities are rare – particularly in this exciting location.”

Pfizer plans to move its employees in by December 2018 when building works are expected to be completed.

Must Read

New regional roadmaps for prioritising antimicrobial resistance

0
A new publication by the International Pharmaceutical Federation (FIP) identifies priority actions pharmacists should take to minimise antimicrobial resistance (AMR). The publication presents six...